CPS / Child-Welfare Drug Testing

Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated August 2026

Quick answer: Child-welfare testing runs on risk triggers and court orders — meconium/cord toxicology for newborns, parental panels with reunification stakes.

Trigger points

Reports alleging caregiver impairment launch assessments: newborn toxicology, parental urine panels, hair testing (90-day histories persuade judges), and home-study observations combine into dependency petitions.

Your procedural rights

Consent matters: refuse voluntary testing and CPS needs court orders (which emergency circumstances expedite). Split-specimen disputes, prescription documentation and MRO-style reviews apply less formally here — attorneys matter earlier than in employment cases.

Reunification timelines

Clean-test streak requirements (typically 90–180 consecutive days) drive reunification plans; missed drops reset clocks in most jurisdictions — consistency outranks perfection arguments.

Certified labs nationwide · Results in 1–2 days

Need a test? Order online, test same-day →
Medical disclaimer: DrugPanels provides educational information about laboratory drug testing and does not offer medical advice, diagnosis, or treatment. Detection windows are population ranges — individual results vary with metabolism, dose, frequency and health status. Never stop prescribed medication to pass a test without talking to your prescriber. Affiliate disclosure: some links on this page are affiliate links; if you order through them we may earn a commission at no additional cost to you.

People also ask

Do prescriptions count against me?

No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.

Sources & further reading

  • SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
  • DOT — 49 CFR Part 40 procedures for transportation workplace testing
  • Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
  • FDA — drug-of-abuse test device labeling (detection window conventions)